1.Diagnosis and treatment of autoimmune hemolytic anemia: classic approach and recent advances.
Blood Research 2016;51(2):69-71
No abstract available.
Anemia, Hemolytic, Autoimmune*
;
Diagnosis*
2.Acute Ischemic Stroke Showing Microembolic Signals in a Patient With Autoimmune Hemolytic Anemia.
Hyung Jun KIM ; Ho Sik SHIN ; Dong Hyun LEE
Journal of the Korean Neurological Association 2014;32(3):182-185
Autoimmune hemolytic anemia (AIHA) can be considered in the differential diagnosis of hemolytic anemia with a concomitant cerebral infarction. We report a 79-year-old woman who was stuporous at presentation, and ultimately diagnosed with AIHA and cerebral infarction. Microembolic signals (MES) were detected by transcranial Doppler monitoring on the first hospitalization day. MES disappeared on the sixth hospitalization day following treatment with steroid and anticoagulation. This case represents a rare arterial ischemic complication of AIHA possibly associated with a hypercoagulable state.
Aged
;
Anemia, Hemolytic
;
Anemia, Hemolytic, Autoimmune*
;
Cerebral Infarction
;
Diagnosis, Differential
;
Female
;
Hospitalization
;
Humans
;
Stroke*
;
Stupor
;
Thrombophilia
3.Autoimmune Hemolytic Anemia in Children.
Dong Chul PARK ; Chang Hyun YANG ; Kir Young KIM
Yonsei Medical Journal 1987;28(4):313-321
The purpose of this study was to review the clinical hematological, immunological features and treatment responsiveness in children with autoimmune hemolytic anemia (AHA). Eight children with AHA and positive Coombs' test was evaluated. Seven patients presented with acute onset of symptoms and histories of infection. One case was diagnosed as Evans syndrome, one as a chromosomal anomaly, and one case was combined with the Guillain-Barre syndrome. Among 8 the patients, 4 exhibited warm antibodies and the remainder had cold antibodies. The patients were given washed packed red blood cells, prednisolone or immunosuppressive drugs (6-MP or cyclophosphamide). Five patients responded well to transfusion and/or prednisolone, one patient died and one patient showed no response in 5 months of follow up.
Adolescent
;
Anemia, Hemolytic, Autoimmune/blood
;
Anemia, Hemolytic, Autoimmune/diagnosis*
;
Anemia, Hemolytic, Autoimmune/therapy
;
Child
;
Child, Preschool
;
Coombs' Test
;
Female
;
Human
;
Infant
;
Male
;
Retrospective Studies
4.Hemolytic anemia in pediatrics.
Korean Journal of Pediatrics 2007;50(6):511-518
To understand the hemolytic anemia (HA) in children, the diagnostic approach and management of hereditary and acquired HA are described. The hereditary hemolytic anemia (HHA) can be classified according to the pathogenesis into three types:RBC membrane defects, hemoglobinopathies, and RBC enzymopathies. Clinical characteristics, laboratory findings and molecular defects of these three types are presented briefly. In Korea, HHA due to the RBC membrane defect, hereditary spherocytosis had been reported often but HHA due to hemoglobinopathies and RBC enzymopathies had been thought to be relatively rare. With recent development in the molecular diagnosis, beta thalassemia, mostly heterozygote, G6PD and pyruvate kinase deficiency have been reported with gene characterization. If the patients with microcytic hypochromic anemia show unproportionally low MCV or MCH or refractory to the iron therapy, hemoglobin electrophoresis and gene analysis for thalassemia or other unstable hemoglobinopathies need to be done accordingly. The global movement of the population especially from the region prevalent of hemoglobinopathies or enzymopathies to Korea warrants considering broad spectrum of etiology for the diagnosis of HHA. Aquired HA resulting from extracellular factors such as autoimmune HA from warm antibody, cold agglutinin and paroxysmal cold hemoglobinuria as well as nonimmune HA are described briefly.
Anemia, Hemolytic*
;
Anemia, Hemolytic, Autoimmune
;
Anemia, Hemolytic, Congenital
;
Anemia, Hypochromic
;
beta-Thalassemia
;
Child
;
Diagnosis
;
Electrophoresis
;
Hemoglobinopathies
;
Hemoglobinuria, Paroxysmal
;
Heterozygote
;
Humans
;
Iron
;
Korea
;
Membranes
;
Pediatrics*
;
Pyruvate Kinase
;
Thalassemia
5.Sjögren's syndrome combined with cold agglutinin disease: A case report.
Li Fang WANG ; Lian Jie SHI ; Wu NING ; Nai Shu GAO ; Kuan Ting WANG
Journal of Peking University(Health Sciences) 2023;55(6):1130-1134
Sjögren's syndrome(SS)is a chronic autoimmune disease that affects exocrine glands, especially salivary and lacrimal glands. The main clinical manifestations are dry mouth and dry eyes, but also multi-organ and multi-system can be involved. Cold agglutinin disease(CAD)is an autoimmune disease characterized by red blood cell agglutination in the blood vessels of extremities caused by cold agglutinin at low temperature, resulting in skin microcirculation disturbance, or hemolytic anemia. Cold agglutinin disease is divided into two categories, primary cold agglutinin disease and secondary cold agglutinin disease. Primary cold agglutinin disease is characterized with cold agglutinin titer of 1 ∶4 000 or more and positive Coomb's test. However, the Coomb's test is not necessarily positive and the cold agglutinin titer is between 1 ∶32 and 1 ∶4 000 in secondary cold agglutinin disease. Here, we reported an elderly patient admitted to hospital due to fever. He was diagnosed with respiratory infection, but he showed incompletely response to the anti-infection treatment. Further laboratory tests showed the patient with positive ANA and anti-SSA antibodies. Additionally, the patient complained that he had dry mouth and dry eyes for 1 year. Schirmer test and salivate gland imaging finally confirmed the diagnosis Sjogren's syndrome. During the hospital stay, the blood clots were found in the anticoagulant tubes. Hemolytic anemia was considered as the patient had anemia with elevated reticulocytes and indirect bilirubin. In addition, further examination showed positive cold agglutination test with a titer of 1 ∶1 024, and cold agglutinin disease was an important type of cold-resistant autoimmune hemolytic anemia. Furthermore, the patient developed cyanosis after ice incubating at the tip of the nose. Hence, the patient was diagnosed as CAD and he was successfully treated with glucocorticoids instead of anti-infection treatments. Hence, the patient was diagnosed with SS combined with secondary CAD. SS combined CAD are rarely reported, and they are both autoimmune diseases. The abnormal function of B lymphocytes and the production of autoantibodies might be the common pathogenesis of them. Cold agglutinin disease can lead to severe hemolytic anemia, even life-threatening. In clinical practice, timely recognizing and dealing with CAD might promote the prognosis of the patient.
Male
;
Humans
;
Aged
;
Anemia, Hemolytic, Autoimmune/diagnosis*
;
Sjogren's Syndrome/diagnosis*
;
Anemia, Hemolytic/complications*
;
Dry Eye Syndromes/complications*
;
Autoantibodies
6.Early Diagnosis of One Multiple Myeloma Patient with Cold Agglutinin Syndrome as the Initial Presentation.
Journal of Experimental Hematology 2021;29(3):787-790
OBJECTIVE:
To analyze one case of multiple myeloma (MM) initially presenting cold agglutinin syndrome (CAS), so as to improve clinical understanding and screening of this disease.
METHODS:
The clinical data, laboratory examination, bone marrow result, diagnosis and treatment of the patient were analyzed and summarized to provide ideas and clinical experience for the early diagnosis and treatment of CAS secondary to MM.
RESULTS:
The clinical manifestations of asthenia, hemolysis, jaundice and scattered livedo reticularis were caused by CAS secondary to MM, which was different from the general Raynaud's phenomenon. IgMκ type MM was definitely diagnosed according to the morphological features of bone marrow cells and immunofixation electrophoresis. After 3 courses of chemotherapy with BAD regimen and enhanced thermal support, anemia was corrected, M protein was decreased and the cold agglutinin phenomenon was significantly reduced. The evaluation of efficacy reached very good partial response.
CONCLUSION
There are very few MM patients with CAS as the initial presentation, so it is easy to misdiagnose. Early diagnosis and individual therapy are particularly important, which requires clinicians to observe and gain experience further.
Anemia, Hemolytic, Autoimmune/diagnosis*
;
Cryoglobulins
;
Early Diagnosis
;
Humans
;
Multiple Myeloma/diagnosis*
7.IgG4-related diseases with autoimmune hemolytic anemia: A case report.
Manxuan PEND ; Lizhen YANG ; Shangjie WU
Journal of Central South University(Medical Sciences) 2020;45(6):739-744
IgG4-related disease (IgG4-RD) is a rare autoimmune fibrosis disease characterized by elevated serum IgG4 and tissues as well as organs infiltrated with IgG4-positive cells, resulting in swelling and damage.It is currently treated as first-line treatment with glucocorticoids. Autoimmune hemolytic anemia (AIHA) is also a relatively rare disease that caused by autoreactive erythrocyte antibodies. Although both are autoimmune-related diseases, they rarely overlap. The relationship between them is not clear. A case of IgG4-RD combined with AIHA is reported. The patient has shortness of breath, cough, and sputum after physical activity. Physical examination showed appearance of anemia, yellow staining of skin and sclera, palpable neck and multiple swollen lymph nodes. Laboratory examination, bone marrow biopsy, and lymph node biopsy confirmed the diagnosis. Therefore, clinicians should develop ideas and raise awareness of such diseases.
Anemia, Hemolytic, Autoimmune
;
diagnosis
;
drug therapy
;
Autoimmune Diseases
;
complications
;
Biopsy
;
Humans
;
Immunoglobulin G
;
Immunoglobulin G4-Related Disease
;
complications
;
diagnosis
10.Treatment of autoimmune hemolytic anemia: real world data from a reference center in Mexico
José Carlos JAIME-PÉREZ ; Patrizia AGUILAR-CALDERÓN ; Lorena SALAZAR-CAVAZOS ; Andrés GÓMEZ-DE LEÓN ; David GÓMEZ-ALMAGUER
Blood Research 2019;54(2):131-136
BACKGROUND: Warm autoimmune hemolytic anemia (w-AIHA) is an uncommon disease with heterogeneous response to treatment. Steroids are the standard treatment at diagnosis, whereas rituximab has recently been recommended as the second-line therapy of choice. Our main objective was to document the response to treatment in patients with newly diagnosed w-AIHA, including the effectiveness of low-dose rituximab as frontline treatment and for refractory disease. METHODS: Patients with w-AIHA from 2002 to 2017 were included. Relapse-free survival (RFS), probability of maintained response (MR), and time-to-response were analyzed using the Kaplan–Meier method. Response was classified as complete, partial, and no response. RESULTS: We included 64 adults with w-AIHA (39 women and 25 men). The median age was 37 (16–77) years. Response rates to steroids alone were 76.7%, rituximab plus steroids, 100%; and cyclophosphamide, 80%. RFS with steroids at 6, 36, and 72 months was 86.3%, 65.1%, and 59.7%, respectively. Eighteen patients received rituximab at 100 mg/wk for 4 weeks plus high-dose dexamethasone as first-line therapy, with RFS at 6, 36, and 72 months of 92.3%, 58.7% and 44.1%, respectively. Eight patients refractory to several lines of therapy were treated with low-dose rituximab, and all achieved a response (three complete response and five partial response) at a median 16 days (95% confidence interval, 14.1–17.8), with a 75% probability of MR at 103 months; the mean MR was 81.93±18 months. CONCLUSION: Outcomes of w-AIHA treatment were considerably heterogeneous. Low rituximab doses plus high dexamethasone doses were effective for refractory disease.
Adult
;
Anemia, Hemolytic, Autoimmune
;
Cyclophosphamide
;
Dexamethasone
;
Diagnosis
;
Female
;
Humans
;
Methods
;
Mexico
;
Rituximab
;
Splenectomy
;
Steroids